Abstract：OBJECTIVE: To determine the molecular mechanisms linking intrauterine growth restriction (IUGR) to adult type 2 diabetes mellitus, the effect of IUGR on the hepatic post-receptor insulin-signaling pathway was investigated in the adult offspring. METHODS: The IUGR model was prepared by maternal protein-malnutrition. Western blotting analysis was undertaken to assess hepatic expression of insulin receptor substrate (IRS-2), phosphoinositol 3-kinase (PI-3K), protein kinase B (PKB), phosphorylated PKB-Ser473 and glycogen synthase kinase (GSK) 3 in 8-week-old male IUGR rats. RESULTS: The basal levels of PI-3K protein decreased in IUGR rats compared with normal controls (P<0.01), whereas GSK-3β protein level significantly increased in IUGR rats (P<0.01). Both PKB and phosphorylated PKB-Ser473 protein levels significantly decreased in the liver of IUGR rats compared with normal controls (P<0.01). After insulin administration, phosphorylated PKB-Ser473 significantly increased to 182% of basal level in control rats (P<0.01); However, phosphorylation of PKB which responded to insulin was markedly blunted in IUGR rats compared with controls and only increased to 123% of basal level (P<0.05). ConclusionsThe level of PI-3K and PKB and phosphorylated PKB-Ser473 expression decreased in the liver of IUGR rats, whereas the levels of GSK-3β protein increased. It may contribute to the pathogenesis of insulin resistance in the IUGR rats.［Chin J Contemp Pediatr, 2009, 11 (3):221-224］
LIU Xiao-Mei,JIAO Yi-Sheng,PAN Li-Li et al. Perturbed hepatic phosphoinositol 3-kinase signaling pathway in the rat with intrauterine growth restriction[J]. CJCP, 2009, 11(03): 221-224.
［3］Desai M, Gayle D, Babu J, Ross MG. Programmed obesity in intrauterine growth-restricted newborns: modulation by newborn nutrition［J］.Am J Physiol Regul Integr Comp Physiol, 2005, 288(1):R91-96.
［4］Ibáňez L, Ong K, Dunger DB, de Zegher F. Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children［J］.J Clin Endocrinol Metab, 2006, 91(6): 2153-2158.
［5］Matharu K, Ozanne SE.The fetal origins of disease and associations with low birthweight［J］.NeoReviews, 2004, 5(12): 522-526.
［8］Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets［J］. J Clin Endocrinol Metab, 2001, 86 (3):972-979.
［9］Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow［J］. Trends Biochem Sci, 2001, 26 (11):657-664.
［10］Suzuki R, Tobe K, Aoyama M, Inoue A, Sakamoto K, Yamauchi T, et al . Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(-/-) mice［J］. J Biol Chem, 2004, 279(24):25039-25049.
［11］White MF. IRS proteins and the common path to diabetes［J］. Am J Physiol Endocrinol Metab, 2002, 283(3):413-422.
［12］Kaidanovich O, Eldar-Finkelman H．The role of glycogensynthase kinase-3 in insulin resistance and type 2 diabetes［J］．Export Opin Ther Targets, 2002, 6(5): 555-561．
［13］Lochhead PA, Coghlan M, Rice SQJ, Sutherland C. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression［J］. Diabetes, 2001, 50(5):937-946.
［14］Kaidanovich-Beilin O, Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle ［J］. J Pharmacol Exp Ther, 2006, 316(1):17-24.
［15］Plotkin B, Kaidanovich O, Talior I, Finkelman HE. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3［J］. J Pharmacol Exp Ther, 2003, 305(3):974-980.
